Geneva-based KYLYS raises CHF 1 million to advance regenerative aesthetic medicine
Life sciences
23 June 2025
KYLYS Aesthetics’ team members Eric Allémann, Alexandre and Bryan Porcello, and Olivier Jordan, have secured CHF 1 million in funding to advance its patented hyaluronic acid medical devices for regenerative aesthetic applications. | © KYLYS Aesthetics
Biotech KYLYS Aesthetics has raised CHF 1 million to advance clinical development of its next-generation hyaluronic acid medical devices for regenerative aesthetic medicine.
KYLYS AESTHETICS SA, a Geneva-based biotech company specializing in regenerative aesthetic solutions, has successfully closed a CHF 1 million fundraising round to support the development and clinical validation of its lead medical device. The round includes support from FONGIT, The Berlin Angel Fund, Business Angel Club Berlin-Brandenburg, and other private and strategic investors.
Founded in 2023 as a spin-off from the University of Geneva, KYLYS is developing Class III medical devices and cosmeceutical products based on a proprietary hyaluronic acid (HA) technology. Its injectable solution is designed to improve the safety, longevity, and natural appearance of aesthetic procedures by using a novel HA formulation that allows for ultra-fine needle application.
The company previously received a seed loan from the Fongit Innovation Fund (FIF), backed by the State of Geneva and aligned with the UN Sustainable Development Goals. This new round of funding reflects continued confidence in KYLYS’s vision and marks an important step in the company’s path to market.
The financing will be used to advance clinical trials, support regulatory filings, and prepare for market entry. It will also help expand KYLYS’s product pipeline in the fast-growing field of regenerative aesthetics, a sector combining biotechnology, dermatology, and medical devices.
In addition to investor support, KYLYS benefits from a strong Swiss innovation ecosystem. It has received backing from Innosuisse, Venturelab, Swissnex, the University of Bern, sitem-insel, OPI, and the Genolier Innovation Hub, reflecting broad institutional support for deep-tech entrepreneurship in the health and life sciences sectors.
With a growing reputation for scientific excellence and product innovation, KYLYS is emerging as one of Western Switzerland’s most promising start-ups in medtech and aesthetic biotechnology. Its latest funding milestone positions the company to further contribute to Geneva’s dynamic life sciences ecosystem and the global shift toward safe, sustainable, and science-backed beauty solutions.
